{"product_id":"luciribo-ribociclib","title":"LuciRibo (Ribociclib)","description":"\u003ch2\u003eAbout Ribociclib\u003c\/h2\u003e\u003cp\u003eRibociclib is a targets proteins called cyclin dependant kinase 4 and cyclin dependant 6 (CDK 4 and CDK 6) on breast cancer cells. CDK 4 and CDK 6 are proteins that stimulate cancer cells to divide and grow. Ribociclib works by blocking these proteins.\u003c\/p\u003e\u003ch3\u003eBreast Cancer\u003c\/h3\u003e\u003ch4\u003eEarly breast cancer\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated in combination with an aromatase inhibitor for the adjuvant treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence\u003c\/li\u003e\n\u003cli\u003e400 mg PO daily for 21 consecutive days followed by 7 days off treatment\u003c\/li\u003e\n\u003cli\u003eRepeat in 28-day cycles for 3 years or until disease recurrence or unacceptable toxicity\u003c\/li\u003e\n\u003cli\u003eRefer to prescribing information for the recommended dose of the aromatase inhibitor\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eAdvanced or metastatic breast cancer\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIndicated for HR-positive, HER2-negative advanced or metastatic breast cancer\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eIn combination with an aromatase inhibitor as initial endocrine-based therapy\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003e600 mg PO daily for 21 consecutive days followed by 7 days off treatment\u003c\/li\u003e\n\u003cli\u003eRepeat in 28-day cycles until disease recurrence or unacceptable toxicity\u003c\/li\u003e\n\u003cli\u003eRefer to prescribing information for the recommended dose of the aromatase inhibitor\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eIn combination with fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003e600 mg PO daily for 21 consecutive days followed by 7 days off treatment; repeat in 28-day cycles until disease recurrence or unacceptable toxicity, \u003cstrong\u003ePLUS\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eFulvestrant 500 mg IM on Days 1,15, and 29, followed by 500 mg IM monthly thereafter\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003cp\u003eReview the prescribing information for the coadministered aromatase inhibitor or fulvestrant for dosage modifications\u003c\/p\u003e\u003ch4\u003eRecommended dose modifications for adverse effects\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eEarly breast cancer\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eStarting dose: 400 mg\/day\u003c\/li\u003e\n\u003cli\u003eDose reduction: 200 mg\/day; discontinue if further dose adjustment is required\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eAdvanced or metastatic breast cancer\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eStarting dose: 600 mg\/day\u003c\/li\u003e\n\u003cli\u003eFirst dose reduction: 400 mg\/day\u003c\/li\u003e\n\u003cli\u003eSecond dose reduction: 200 mg\/day; discontinue if further dose adjustment is required\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797954883627,"sku":"RL3120250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-0937.jpg?v=1787022230","url":"https:\/\/xomeds.com\/products\/luciribo-ribociclib","provider":"XOMEDS","version":"1.0","type":"link"}